Elutia Inc. (NASDAQ:ELUT) Shares Bought by Arcus Capital Partners LLC

Arcus Capital Partners LLC increased its stake in shares of Elutia Inc. (NASDAQ:ELUT) by 100.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,000 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Arcus Capital Partners LLC owned about 0.06% of Elutia worth $76,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ELUT. Renaissance Technologies LLC boosted its stake in Elutia by 50.5% during the second quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock valued at $266,000 after buying an additional 18,000 shares in the last quarter. Perkins Capital Management Inc. lifted its stake in Elutia by 9.8% during the third quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock valued at $3,263,000 after purchasing an additional 76,450 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in Elutia by 8.8% during the second quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company’s stock worth $8,907,000 after buying an additional 145,697 shares in the last quarter. Finally, AIGH Capital Management LLC grew its position in Elutia by 288.8% in the second quarter. AIGH Capital Management LLC now owns 1,697,316 shares of the company’s stock worth $8,419,000 after buying an additional 1,260,750 shares during the last quarter. Institutional investors own 74.03% of the company’s stock.

Elutia Stock Performance

Shares of NASDAQ:ELUT opened at $3.80 on Tuesday. Elutia Inc. has a 52 week low of $1.39 and a 52 week high of $5.24. The company has a market cap of $129.43 million, a PE ratio of -1.33 and a beta of 0.76. The firm has a 50 day simple moving average of $3.76 and a 200 day simple moving average of $3.67.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 target price on shares of Elutia in a report on Friday, September 6th.

Elutia Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.